Seminars in Radiation Oncology
Volume 18, Issue 2 , Pages 75-88 , April 2008

From Cellular to High-Throughput Predictive Assays in Radiation Oncology: Challenges and Opportunities

  • Søren M. Bentzen, PhD, DSc

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Søren M. Bentzen, Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, K4/316 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792.

References 

  1. Bentzen SM. Preventing or reducing late side effects of radiation therapy: Radiobiology meets molecular pathology. Nat Rev Cancer. 2006;6:702–713
  2. Kolch W, Mischak H, Pitt AR. The molecular make-up of a tumour: Proteomics in cancer research. Clin Sci (Lond). 2005;108:369–383
  3. Sakaki Y, Kholodenko BN, Hatakeyama M, et al. The International Consortium on Systems Biology of Receptor Tyrosine Kinase Regulatory Networks. IEE Proc Syst Biol. 2005;152:53–54
  4. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–578
  5. Bentzen SM. Radiation therapy: Intensity modulated, image guided, biologically optimized and evidence based. Radiother Oncol. 2005;77:227–230
  6. Bentzen SM. High-tech in radiation oncology: Should there be a ceiling?. Int J Radiat Oncol Biol Phys. 2004;58:320–330
  7. Bentzen SM. Theragnostic imaging for radiation oncology: Dose-painting by numbers. Lancet Oncol. 2005;6:112–117
  8. Munro TR, Gilbert CW. The relation between tumour lethal doses and the radiosensitivity of tumour cells. Br J Radiol. 1961;34:246–251
  9. Thames HD, Hendry JH. Fractionation in Radiotherapy. London: Taylor & Francis; 1987;1-1
  10. Fertil B, Malaise EP. Inherent radiosensitivity as a basic concept for human tumor radiotherapy. Int J Radiat Oncol Biol Phys. 1981;7:621–629
  11. West CML, Davidson SE, Hendry JH, et al. Prediction of cervical carcinoma response to radiotherapy. Lancet. 1991;338:818
  12. Begg AC, Haustermans K, Hart AA, et al. The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: A multicenter analysis. Radiother Oncol. 1999;50:13–23
  13. Burnet NG, Nyman J, Turesson I, et al. Prediction of normal-tissue tolerance to radiotherapy from in-vitro cellular radiation sensitivity. Lancet. 1992;339:1570–1571
  14. Geara FB, Peters LJ, Ang KK, et al. Prospective comparison of in vitro normal cell radiosensitivity and normal tissue reactions in radiotherapy patients. Int J Radiat Oncol Biol Phys. 1993;27:1173–1179
  15. Johansen J, Bentzen SM, Overgaard J, et al. Relationship between the in vitro radiosensitivity of skin fibroblasts and the expression of subcutaneous fibrosis, telangiectasia, and skin erythema after radiotherapy. Radiother Oncol. 1996;40:101–109
  16. Johansen J, Bentzen SM, Overgaard J, et al. Evidence for a positive correlation between in vitro radiosensitivity of normal human skin fibroblasts and the occurrence of subcutaneous fibrosis after radiotherapy. Int J Radiat Biol. 1994;66:407–412
  17. Brock WA, Tucker SL, Geara FB, et al. Fibroblast radiosensitivity versus acute and late normal skin responses in patients treated for breast cancer. Int J Radiat Oncol Biol Phys. 1995;32:1371–1379
  18. Russell NS, Grummels A, Hart AA, et al. Low predictive value of intrinsic fibroblast radiosensitivity for fibrosis development following radiotherapy for breast cancer. Int J Radiat Biol. 1998;73:661–670
  19. Peacock J, Ashton A, Bliss J, et al. Cellular radiosensitivity and complication risk after curative radiotherapy. Radiother Oncol. 2000;55:173–178
  20. Nordsmark M, Bentzen SM, Overgaard J. Measurement of human tumour oxygenation status by a polarographic needle electrode (An analysis of inter- and intratumour heterogeneity). Acta Oncol. 1994;33:383–389
  21. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy (An international multi-center study). Radiother Oncol. 2005;77:18–24
  22. Nordsmark M, Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol. 2000;57:39–43
  23. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 1996;41:31–39
  24. Harris AL. Hypoxia—a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2:38–47
  25. Koukourakis MI, Bentzen SM, Giatromanolaki A, et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol. 2006;24:727–735
  26. Moeller BJ, Dreher MR, Rabbani ZN, et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell. 2005;8:99–110
  27. Ataman OU, Bentzen SM, Saunders MI, et al. Failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (CHART) or conventional radiotherapy in locally advanced non-small-cell lung cancer: A competing risks analysis. Br J Cancer. 2001;85:1113–1118
  28. Ataman OU, Bentzen SM, Wilson GD, et al. Molecular biomarkers and site of first recurrence after radiotherapy for head and neck cancer. Eur J Cancer. 2004;40:2734–2741
  29. Schechter AL, Hung MC, Vaidyanathan L, et al. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science. 1985;229:976–978
  30. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182
  31. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672
  32. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–1684
  33. Chien KR. Herceptin and the heart—A molecular modifier of cardiac failure. N Engl J Med. 2006;354:789–790
  34. Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors: Role of hypoxia and anemia. Med Oncol. 2001;18:243–259
  35. Crawford J. Erythropoietin: High profile, high scrutiny. J Clin Oncol. 2007;25:1021–1023
  36. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255–1260
  37. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007;25:1027–1032
  38. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol. 2005;23:5960–5972
  39. Goldberg P. Danish researchers post long-awaited Aranesp results—Ever so discreetly. The Cancer Letter. 2007;33:1–7
  40. Henke M, Mattern D, Pepe M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. J Clin Oncol. 2006;24:4708–4713
  41. Deeken JF, Figg WD, Bates SE, et al. Toward individualized treatment: Prediction of anticancer drug disposition and toxicity with pharmacogenetics. Anticancer Drugs. 2007;18:111–126
  42. Sugiyama E, Kaniwa N, Kim SR, et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: The impact of a cytidine deaminase polymorphism. J Clin Oncol. 2007;25:32–42
  43. Overgaard J, Eriksen JG, Nordsmark M, et al. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: Results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol. 2005;6:757–764
  44. Buffa FM, Bentzen SM, Daley FM, et al. Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy. Clin Cancer Res. 2004;10:3745–3754
  45. Harari PM, Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys. 2001;49:427–433
  46. Schmidt-Ullrich RK, Contessa JN, Lammering G, et al. ERBB receptor tyrosine kinases and cellular radiation responses. Oncogene. 2003;22:5855–5865
  47. Bentzen SM. Repopulation in radiation oncology: Perspectives of clinical research. Int J Radiat Biol. 2003;79:581–585
  48. Bentzen SM, Atasoy BM, Daley FM, et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol. 2005;23:5560–5567
  49. Eriksen JG, Steiniche T, Askaa J, et al. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys. 2004;58:561–566
  50. Eriksen JG, Steiniche T, Overgaard J. The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinoma of the head and neck in the randomized DAHANCA 6 and 7 study. Radiother Oncol. 2005;74:93–100
  51. Dische S, Saunders MI, Barrett A, et al. A randomized multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol. 1997;44:123–136
  52. Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet. 2003;362:933–940
  53. Atkins D, Reiffen KA, Tegtmeier CL, et al. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: Variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem. 2004;52:893–901
  54. Chua DT, Nicholls JM, Sham JS, et al. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59:11–20
  55. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62:7350–7356
  56. van’t Veer L, Dai H, van d V, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–536
  57. Abdullah-Sayani A, Bueno-de-Mesquita JM, van de Vijver M. Technology Insight: Tuning into the genetic orchestra using microarrays—Limitations of DNA microarrays in clinical practice. Nat Clin Pract Oncol. 2006;3:501–516
  58. van de Vijver M, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009
  59. Buyse M, Loi S, van’t VL, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 2006;98:1183–1192
  60. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005;365:671–679
  61. Desmedt C, Piette F, Loi S, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res. 2007;13:3207–3214
  62. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006;355:560–569
  63. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: A multiple random validation strategy. Lancet. 2005;365:488–492
  64. Eden P, Ritz C, Rose C, et al. “Good old” clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer. 2004;40:1837–1841
  65. Dunkler D, Michiels S, Schemper M. Gene expression profiling: Does it add predictive accuracy to clinical characteristics in cancer prognosis?. Eur J Cancer. 2007;43:745–751
  66. Michiels S, Koscielny S, Hill C. Interpretation of microarray data in cancer. Br J Cancer. 2007;96:1155–1158
  67. Benjamin Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Stat Soc B. 2007;57:289–300
  68. Bentzen SM. Prognostic factor studies in oncology. Int J Radiat Oncol Biol Phys. 2001;49:513–518
  69. Pawitan Y, Michiels S, Koscielny S, et al. False discovery rate, sensitivity and sample size for microarray studies. Bioinformatics. 2005;21:3017–3024
  70. Sargent DJ, Conley BA, Allegra C, et al. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol. 2005;23:2020–2027
  71. Bogaerts J, Cardoso F, Buyse M, et al. Gene signature evaluation as a prognostic tool: Challenges in the design of the MINDACT trial. Nat Clin Pract Oncol. 2006;3:540–551
  72. Trott KR. Tumour stem cells: The biological concept and its application in cancer treatment. Radiother Oncol. 1994;30:1–5
  73. Denekamp J. Tumour stem cells: Facts, interpretation and consequences. Radiother Oncol. 1994;30:6–10
  74. Dirks PB. Cancer: Stem cells and brain tumours. Nature. 2006;444:687–688
  75. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756–760
  76. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396–401
  77. Krause M, Prager J, Zhou X, et al. EGFR-TK inhibition before radiotherapy reduces tumour volume but does not improve local control: Differential response of cancer stem cells and nontumourigenic cells?. Radiother Oncol. 2007;83:316–325
  78. Safwat A, Bentzen SM, Turesson I, et al. Deterministic rather than stochastic factors explain most of the variation in the expression of skin telangiectasia after radiotherapy. Int J Radiat Oncol Biol Phys. 2002;52:198–204
  79. Bentzen SM, Dorr W, Anscher MS, et al. Normal tissue effects: Reporting and analysis. Semin Radiat Oncol. 2003;13:189–202
  80. Trotti A, Bentzen SM. The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol. 2004;22:19–22
  81. Bentzen SM, Overgaard J. Patient-to-patient variability in the expression of radiation-induced normal-tissue injury. Semin Radiat Oncol. 1994;4:68–80
  82. Holscher T, Bentzen SM, Baumann M. Influence of connective tissue diseases on the expression of radiation side effects: A systematic review. Radiother Oncol. 2006;78:123–130
  83. Bentzen SM, Overgaard M, Thames HD. Fractionation sensitivity of a functional endpoint: Impaired shoulder movement after postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys. 1989;17:531–537
  84. Honore HB, Bentzen SM, Moller K, et al. Sensori-neural hearing loss after radiotherapy for nasopharyngeal carcinoma: Individualized risk estimation. Radiother Oncol. 2002;65:9–16
  85. Kruglyak L, Nickerson DA. Variation is the spice of life. Nat Genet. 2001;27:234–236
  86. Hinds DA, Stuve LL, Nilsen GB, et al. Whole-genome patterns of common DNA variation in three human populations. Science. 2005;307:1072–1079
  87. Houlston RS, Peto J. The search for low-penetrance cancer susceptibility alleles. Oncogene. 2004;23:6471–6476
  88. Imyanitov EN, Togo AV, Hanson KP. Searching for cancer-associated gene polymorphisms: promises and obstacles. Cancer Lett. 2004;204:3–14
  89. Ross JS, Schenkein DP, Kashala O, et al. Pharmacogenomics. Adv Anat Pathol. 2004;11:211–220
  90. Andreassen CN. Can risk of radiotherapy-induced normal tissue complications be predicted from genetic profiles?. Acta Oncol. 2005;44:801–815
  91. Bahlo M, Stankovich J, Speed TP, et al. Detecting genome wide haplotype sharing using SNP or microsatellite haplotype data. Hum Genet. 2006;119:38–50
  92. Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. Nat Rev Genet. 2005;6:95–108
  93. Wang WY, Barratt BJ, Clayton DG, et al. Genome-wide association studies: Theoretical and practical concerns. Nat Rev Genet. 2005;6:109–118
  94. Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661–678
  95. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007;447:1087–1093
  96. West CM, McKay MJ, Holscher T, et al. Molecular markers predicting radiotherapy response: Report and recommendations from an International Atomic Energy Agency technical meeting. Int J Radiat Oncol Biol Phys. 2005;62:1264–1273
  97. Ho AY, Atencio DP, Peters S, et al. Genetic predictors of adverse radiotherapy effects: The Gene-PARE project. Int J Radiat Oncol Biol Phys. 2006;65:646–655
  98. Burnet NG, Elliott RM, Dunning A, et al. Radiosensitivity, radiogenomics and RAPPER. Clin Oncol (R Coll Radiol). 2006;18:525–528
  99. Andreassen CN, Alsner J, Overgaard M, et al. Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother Oncol. 2003;69:127–135
  100. Andreassen CN, Alsner J, Overgaard M, et al. Risk of radiation-induced subcutaneous fibrosis in relation to single nucleotide polymorphisms in TGFB1. SOD2, XRCC1, XRCC3, APEX and ATM—A study based on DNA from formalin fixed paraffin embedded tissue samples Int J Radiat Biol. 2006;82:577–586
  101. Quarmby S, Fakhoury H, Levine E, et al. Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients. Int J Radiat Biol. 2003;79:137–143
  102. Giotopoulos G, Symonds RP, Foweraker K, et al. The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes. Br J Cancer. 2007;96:1001–1007
  103. Andreassen CN, Alsner J, Overgaard J, et al. TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother Oncol. 2005;75:18–21
  104. Andreassen CN, Overgaard J, Alsner J, et al. ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys. 2006;64:776–783
  105. Damaraju S, Murray D, Dufour J, et al. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res. 2006;12:2545–2554
  106. Moher D, Jones A, Lepage L. Use of the CONSORT statement and quality of reports of randomized trials: A comparative before-and-after evaluation. JAMA. 2001;285:1992–1995
  107. Bentzen SM. Towards evidence based radiation oncology: Improving the design, analysis, and reporting of clinical outcome studies in radiotherapy. Radiother Oncol. 1998;46:5–18
  108. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies. (REMARK) J Natl Cancer Inst. 2005;97:1180–1184

PII: S1053-4296(07)00094-X

doi: 10.1016/j.semradonc.2007.10.003

Seminars in Radiation Oncology
Volume 18, Issue 2 , Pages 75-88 , April 2008

Article Tools

* Image Usage & Resolution